Summary:
- Merck, a major pharmaceutical company, is planning to start Phase 3 clinical trials for an investigational once-monthly treatment.
- This new treatment is being developed to potentially help patients who need regular medication, as it would only require a monthly dose instead of more frequent dosing.
- Successful completion of the Phase 3 trials could lead to the new treatment being approved for use, providing a more convenient option for patients who require regular medication.